Key Points
- Director purchase: Organogenesis director Michael Joseph Driscoll bought 10,000 shares on March 9 at $2.67 each (total $26,700), increasing his direct stake to 225,707 shares — a 4.64% rise — in a transaction disclosed to the SEC.
- Company performance & market view: Organogenesis beat the quarter with $0.31 EPS and $225.61M revenue, though analysts expect -0.07 EPS for the current year; the stock trades near $2.68 with a $344.1M market cap and a consensus "Moderate Buy" rating with an $8.50 average price target.
Organogenesis (NASDAQ:ORGO - Get Free Report) Director Michael Joseph Driscoll purchased 10,000 shares of Organogenesis stock in a transaction that occurred on Monday, March 9th. The shares were purchased at an average cost of $2.67 per share, with a total value of $26,700.00. Following the transaction, the director directly owned 225,707 shares of the company's stock, valued at $602,637.69. This represents a 4.64% increase in their ownership of the stock. The acquisition was disclosed in a document filed with the SEC, which is accessible through this link.
Organogenesis Stock Up 0.2%
NASDAQ ORGO traded up $0.01 during mid-day trading on Thursday, reaching $2.68. The stock had a trading volume of 220,886 shares, compared to its average volume of 735,988. The stock has a market cap of $344.11 million, a PE ratio of 33.44 and a beta of 1.43. Organogenesis has a 1 year low of $2.61 and a 1 year high of $7.08. The company has a debt-to-equity ratio of 0.04, a current ratio of 3.62 and a quick ratio of 3.32. The company has a fifty day moving average price of $3.79 and a 200 day moving average price of $4.48.
Organogenesis (NASDAQ:ORGO - Get Free Report) last issued its earnings results on Thursday, February 26th. The company reported $0.31 EPS for the quarter, beating the consensus estimate of $0.21 by $0.10. The business had revenue of $225.61 million for the quarter, compared to the consensus estimate of $172.68 million. Organogenesis had a return on equity of 21.41% and a net margin of 5.32%. On average, research analysts expect that Organogenesis will post -0.07 earnings per share for the current year.
Wall Street Analyst Weigh In
Several research firms recently commented on ORGO. BTIG Research dropped their price objective on Organogenesis from $9.00 to $8.00 and set a "buy" rating on the stock in a research report on Friday, February 27th. Wall Street Zen upgraded shares of Organogenesis from a "hold" rating to a "buy" rating in a research note on Sunday. Finally, Weiss Ratings raised shares of Organogenesis from a "sell (d+)" rating to a "hold (c)" rating in a report on Friday, February 27th. Two equities research analysts have rated the stock with a Buy rating and one has assigned a Hold rating to the company. According to MarketBeat.com, the stock has a consensus rating of "Moderate Buy" and an average price target of $8.50.
View Our Latest Stock Analysis on Organogenesis
Institutional Investors Weigh In On Organogenesis
Hedge funds have recently added to or reduced their stakes in the stock. Strs Ohio bought a new position in shares of Organogenesis during the 1st quarter valued at $105,000. Acadian Asset Management LLC increased its position in Organogenesis by 3.9% during the second quarter. Acadian Asset Management LLC now owns 2,424,363 shares of the company's stock valued at $8,862,000 after acquiring an additional 91,118 shares during the last quarter. Creative Planning lifted its holdings in Organogenesis by 84.5% in the second quarter. Creative Planning now owns 35,392 shares of the company's stock valued at $130,000 after acquiring an additional 16,205 shares during the period. Cetera Investment Advisers bought a new position in Organogenesis in the second quarter valued at about $222,000. Finally, Catalyst Funds Management Pty Ltd purchased a new position in Organogenesis in the second quarter worth about $63,000. 49.57% of the stock is currently owned by hedge funds and other institutional investors.
About Organogenesis
(
Get Free Report)
Organogenesis Inc operates as a regenerative medicine company focused on the development, manufacturing and commercialization of therapeutic solutions for wound care, surgical repair and sports medicine. The company's product portfolio addresses a range of acute and chronic tissue repair needs, leveraging bioengineered skin substitutes, human placental-derived products and other allografts designed to promote healing and reduce scarring. Organogenesis markets its therapies to hospitals, outpatient clinics, wound care centers and other healthcare providers.
Key offerings include Apligraf, a living skin substitute for treatment of diabetic foot ulcers and venous leg ulcers; Dermagraft, a cryopreserved human fibroblast-derived dermal substitute; Grafix, a placental membrane allograft for complex and chronic wounds; and TheraSkin, a cryopreserved human skin allograft used in surgical and reconstructive procedures.
Featured Stories
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
